Phil Cath lab portrait
Heart Valve Voice Supporter, Phil MacCarthy Discusses the “Perfect Storm” of Valve Disease Treatment Developments with Cardiovascular News
Tuesday 18th July 2017
Heart Valve Voice Supporter and Key Opinion Leader, Professor Phil MacCarthy, Clinical Director of Cardiovascular Services at London Bridge Hospital and Consultant Cardiologist at King's College Hospital, recently discussed the exciting times we are currently seeing with regards to valve disease treatment with leading publication Cardiovascular News.
In the article he explains that with the many advancements being made to help treat patients with heart valve disease such as TAVI, it is now possible to treat more patients than ever before. This means that patients who would have been turned away in the past due to frailty, comorbidities or advanced age, are now able to receive this life changing treatment.
“When we undertook our first TAVI procedure at King’s College Hospital (London, UK) in 2007, the concept was a promising, pioneering idea with limited data to support it—but things have changed in the last 10 years. Patient outcomes have improved exponentially, with survival at one year reaching between 91% and 93%.”
He also explains that it is not only TAVI that is helping to transform the field of interventional cardiology, other treatments such as Transcatheter mitral valve repair and replacement are also making incredible strides in helping to treat more patients.
To read more about the current exciting climate for interventional cardiologists and patients alike, see the Cardiovascular News website here: https://cardiovascularnews.com/europcr-2017-a-golden-era-for-valve-disease-patients/